DNA repair inhibition and cancer therapy

Journal of Photochemistry and Photobiology B: Biology

Volumn 63, Issue 1-3, 2001, Pages 162-170

  Martin, Niall M B ^a  

^a 327 Cambridge Science Park   (United Kingdom)

Author keywords

Cancer Therapy; DNA repair inhibition

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 AMINOBENZAMIDE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ATM PROTEIN; BLEOMYCIN; CAFFEINE; CARMUSTINE; CELL DNA; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; REGULATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG RESISTANCE; EXCISION REPAIR; HUMAN; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 0035472228     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1011-1344(01)00213-5     Document Type: Article

References (90)

1. Cancer therapy on target
2. A new way to combat therapy side effects
3. Cancer genetics
4. Oxidative damage to DNA: Formation, measurement and biological significance
5. Oxidants, oxidative stress and the biology of aging
6. Genome maintenance mechanisms for preventing cancer
7. Distribution of UV light-induced damage in a defined sequence of human DNA: Detection of alkaline-sensitive lesions at pyrimidine nucleoside-cysteine sequences
8. Damage recognition in nucleotide excision repair of DNA
9. The xeroderma pigmentosum group D (XPD) gene: One gene, two functions, three diseases
10. Base excision repair enzymes family portrait integrating the structure and chemistry of an entire DNA repair pathway
11. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
12. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis, lesson from an uncleavable mutant
13. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death
14. Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice
15. Novel inhibitions of poly(ADP-ribose) synthetase
16. Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken
17. Resistance-modifying agents 5′ synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP)
18. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast
19. Dihydroisoquinolines: The design and synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase
20. Role of poly(ADP-ribose)polymerase in cell death
21. 4-Amino-1,8-naphthalimide: A novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer
22. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity bynovel poly(adenosine diphosphoribose)polymerase inhibitions in a panel of human tumor cell lines
23. Enhancement of bleomycin activity by 3-aminobenzamide, a poly(ADP-ribose) synthesis inhibitor, in vitro and in vivo
24. Potentiation of the antitumour activity of cisplatin in mice by 3-aminobenzamide
25. Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide in genotoxicity, antitumour activity and NAD levels in human lymphocytes in vitro and Ehrlich ascites tumour cells in vivo
26. Reduced tumour progression in vivo by inhibitor of poly(ADP-ribose) synthetase (3-aminobenzamide) in combination with X-rays or the cytostatic drug DTIC
27. Chemical approaches to improved radiotherapy
28. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase
29. The world according to PARP
30. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity
31. ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified
32. Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions
33. Loss of poly(ADP-ribose) polymerase-1 causes increased tumor latency in p53 deficient mice
34. The DNA damage response: Putting checkpoints in perspective
35. DNA double strand breaks: Signalling, repair and the cancer connection
36. DNA-PK: At the cross-roads of biochemistry and genetics
37. DNA-PK, ATM and ATR as sensors of DNA damage: Variations on a theme?
38. Activation of the ATM kinase by ionising radiation and phosphorylation of p53
39. Rapid ATM-dependent phosphorylation of MDM2 recedes p53 accumulation in response to DNA damage
40. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks
41. The DNA damage response: Putting checkpoints in perspective
42. ATM: From gene to function
43. Radiosensitivity in ataxia-telangiectasia: A new explanation
44. ATM deficient mice a paradigm of ataxia-telangiectasia
45. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
46. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitivity agent wortmannin
47. Competitive and non competitive inhibition of the DNA-dependent protein kinase
48. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitises murine fibroblasts and human tumor cells to radiation and blocks induction of 53 following DNA damage
49. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells
50. A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitises cells to bleomycin and ionising radiation
51. The action of caffeine on X-irradiated HeLa cells. 1. Delayed inhibition of DNA synthesis
52. Inhibition of ATM and ATR kinase activity by the radiosensitizing agent, caffeine
53. Wortmannin selectively enhances radiation-induced apoptosis in proliferative but not quiescent cells
54. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells
55. Differential sensitivity of p53 (-/-) and p53 (+/+) cells to caffeine-induced radiosensitization and override of G2 delay
56. DNA damage detection by DNA dependent protein kinase and related enzymes
57. Structure of DNA-dependent protein kinase: Implications for its regulation by DNA
58. The DNA-dependent protein kinase: Requirement for DNA ends and associated with Ku antigen
59. Tying loose ends: Roles of Ku and DNA-dependent protein kinase in the repair of double strand breaks
60. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation
61. A targeted DNA-PKcs - Null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination
62. Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes
63. Nonsense mutation at tyr-4046 in the DNA-dependent protein kinase catalytic submit of severe combined immune deficiency mice
64. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
65. 2-M delay
66. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine
67. UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells
68. Cellular response to DNA damage: Cell-cycle checkpoints, apoptosis and the roles of p53 and ATM
69. DNA damage and checkpoint pathways: Molecular anatomy and interactions with repair
70. Cell cycle control and cancer
71. The G2-phase DNA-damage checkpoint
72. Apoptosis in cancer therapy: Crossing the threshold
73. Exploiting cancer cell cycling for selective protection of normal cells
74. Checkpoint pathways come of age
75. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
76. 2 checkpoint-competent cells
77. cdc2 kinase
78. Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms
79. UCN-01, 7-hydroxy-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human cancer cell lines
80. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine
81. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents
82. DNA repair in humans
83. 6-benzylguanine, and ethacrynic acid in haematological malignancies